In the past, real-world outputs from anti-VEGF treatment have not matched the clinical trials results, partly because nAMD and DME disease pathology is not completely addressed by the anti-VEGF monotherapy. As a result, in real world practice, maintenance of vision outcomes in the long-term requires frequent monitoring and intravitreal injections, which imposes a significant burden on patients and caregivers. However, the introduction of faricimab▼ has led to new thinking as the real-world data supports the data from the pivotal studies regarding the efficacy and safety profile of faricimab▼ in heterogeneous real world patient populations. In this symposium, 4 expert panellists review the key data for faricimab▼ from clinical trials and discuss the ways in which it aligns with the results that have been achieved in real world clinical practice.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.